Rate Notice: 5.9% general rate increase Jan 1, 2026 — Learn More
    UNIS logo
    The embectacorp logo features a stylized blue circle with a red and orange gradient inside signifying the companys brand

    Embecta Corp. Dba Embecta Medical Ii

    Global diabetes management company specializing in insulin delivery devices, formed from BD's diabetes care business spinoff in 2022, serving millions of patients worldwide.

    Company Overview

    Embecta Corp is one of the largest pure-play diabetes management companies in the world, spun off from BD (Becton, Dickinson and Company) in April 2022. The company specializes in manufacturing and distributing insulin delivery devices including syringes, pen needles, and innovative patch pump technology, with a nearly century-long heritage in diabetes care dating back to 1924.

    Key Metrics

    450

    Import Shipments

    6

    Distribution Centers

    1.2B

    Annual Revenue

    1924

    Founded

    Company Profile

    Key Milestones

    Important company milestones and achievements.

    Markets Served

    Geographic markets and customer segments served.

    Ownership Structure

    Corporate ownership and organizational structure.

    Sales Channels

    Distribution networks and sales approaches.

    Recent Developments

    Embecta is actively investing in next-generation diabetes management technologies while expanding its global manufacturing capabilities and strengthening partnerships with healthcare providers and payers to improve patient access to insulin delivery solutions.

    Strategic Expansion

    Advancing development of innovative patch pump technology for Type 2 diabetes patients to compete with next-generation continuous glucose monitors and insulin delivery systems, Expanding research and development investments to drive sustainable revenue growth in constant currency terms while maintaining financial flexibility for strategic acquisitions, Strengthening global supply chain infrastructure across manufacturing sites in the United States, Ireland, and China to support growing demand for insulin delivery devices, Enhancing digital health capabilities through the BD Diabetes Care app and exploring partnership opportunities to integrate connected diabetes management solutions

    Market Expansion

    Strategic efforts to expand market presence and reach new customer segments.

    Technology Adoption

    Implementation of advanced technologies to improve service delivery and customer experience.

    Business Information

    Embecta is singularly focused on improving the lives of people living with diabetes through comprehensive insulin delivery solutions. The company maintains manufacturing facilities across the United States, Ireland, and China, supporting a global distribution network that serves diabetes patients worldwide. With an established portfolio of insulin syringes, pen needles, and the BD Diabetes Care app, Embecta combines nearly 100 years of diabetes care expertise with modern innovation. The company leverages existing pharmacy channel relationships and payer connections to deliver accessible diabetes management solutions while investing in next-generation technologies like patch pump systems for Type 2 diabetes patients.

    Headquarters

    New Jersey and Massachusetts

    Founded

    1924

    Stock Symbol

    EMBC